Class information for: |
Basic class information |
| ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
|---|---|---|---|
| 10393 | 1001 | 35.0 | 60% |
Classes in level above (level 2) |
Terms with highest relevance score |
| Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|---|
| 1 | FENOFIBRIC ACID | Author keyword | 35 | 64% | 3% | 35 |
| 2 | FENOFIBRATE | Author keyword | 29 | 19% | 14% | 140 |
| 3 | FIBRATES | Author keyword | 12 | 15% | 7% | 74 |
| 4 | BEZAFIBRATE | Author keyword | 9 | 17% | 5% | 47 |
| 5 | INTERNAL MED CLIN PHARMACOL | Address | 8 | 22% | 3% | 32 |
| 6 | CIPROFIBRATE | Author keyword | 5 | 24% | 2% | 20 |
| 7 | MIXED DYSLIPIDEMIA | Author keyword | 5 | 40% | 1% | 10 |
| 8 | FIBRATE | Author keyword | 4 | 14% | 3% | 29 |
| 9 | MICRONIZED FENOFIBRATE | Author keyword | 3 | 50% | 0% | 5 |
| 10 | FIBRATE THERAPY | Author keyword | 3 | 100% | 0% | 3 |
Web of Science journal categories |
Author Key Words |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
|---|---|---|---|---|---|---|---|
| 1 | FENOFIBRIC ACID | 35 | 64% | 3% | 35 | Search FENOFIBRIC+ACID | Search FENOFIBRIC+ACID |
| 2 | FENOFIBRATE | 29 | 19% | 14% | 140 | Search FENOFIBRATE | Search FENOFIBRATE |
| 3 | FIBRATES | 12 | 15% | 7% | 74 | Search FIBRATES | Search FIBRATES |
| 4 | BEZAFIBRATE | 9 | 17% | 5% | 47 | Search BEZAFIBRATE | Search BEZAFIBRATE |
| 5 | CIPROFIBRATE | 5 | 24% | 2% | 20 | Search CIPROFIBRATE | Search CIPROFIBRATE |
| 6 | MIXED DYSLIPIDEMIA | 5 | 40% | 1% | 10 | Search MIXED+DYSLIPIDEMIA | Search MIXED+DYSLIPIDEMIA |
| 7 | FIBRATE | 4 | 14% | 3% | 29 | Search FIBRATE | Search FIBRATE |
| 8 | MICRONIZED FENOFIBRATE | 3 | 50% | 0% | 5 | Search MICRONIZED+FENOFIBRATE | Search MICRONIZED+FENOFIBRATE |
| 9 | FIBRATE THERAPY | 3 | 100% | 0% | 3 | Search FIBRATE+THERAPY | Search FIBRATE+THERAPY |
| 10 | CAS 41859 67 0 | 3 | 60% | 0% | 3 | Search CAS+41859+67+0 | Search CAS+41859+67+0 |
Key Words Plus |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | MICRONIZED FENOFIBRATE | 23 | 41% | 4% | 43 |
| 2 | PRIMARY TYPE IIA | 21 | 90% | 1% | 9 |
| 3 | FENOFIBRATE INCREASES CREATININEMIA | 15 | 82% | 1% | 9 |
| 4 | MIXED DYSLIPIDEMIA | 12 | 44% | 2% | 21 |
| 5 | INCREASES CREATININEMIA | 12 | 86% | 1% | 6 |
| 6 | ABT 335 | 11 | 100% | 1% | 6 |
| 7 | PLUS FENOFIBRATE | 11 | 78% | 1% | 7 |
| 8 | COMBINED HYPERLIPIDEMIA | 8 | 12% | 6% | 62 |
| 9 | GEMFIBROZIL TREATMENT | 8 | 48% | 1% | 12 |
| 10 | FENOFIBRATE | 8 | 13% | 6% | 57 |
Journals |
Reviews |
| Title | Publ. year | Cit. | Active references | % act. ref. to same field |
|---|---|---|---|---|
| Fenofibrate A Review of its Use in Dyslipidaemia | 2011 | 29 | 142 | 51% |
| FENOFIBRATE - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES AND THERAPEUTIC USE IN DYSLIPIDEMIA | 1990 | 126 | 86 | 69% |
| Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis | 2010 | 245 | 36 | 17% |
| Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: A clinical update | 2013 | 15 | 56 | 21% |
| Fibrates Effect on Cardiovascular Risk Is Greater in Patients With High Triglyceride Levels or Atherogenic Dyslipidemia Profile: A Systematic Review and Meta-analysis | 2011 | 30 | 27 | 37% |
| Fenofibrate - A review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus | 2007 | 79 | 141 | 45% |
| Fenofibrate and the kidney: an overview | 2013 | 6 | 76 | 37% |
| Safety considerations with fibrate therapy | 2007 | 102 | 99 | 35% |
| Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction | 2012 | 22 | 83 | 28% |
| Hyperlipidaemia and cardiovascular disease: do fibrates have a role? | 2011 | 8 | 28 | 64% |
Address terms |
| Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | INTERNAL MED CLIN PHARMACOL | 8 | 22% | 3.2% | 32 |
| 2 | ST NIKOLAUS STIFTSHOSP GMBH | 3 | 100% | 0.3% | 3 |
| 3 | ISRAELI SOC PREVENT HEART ATTACKS | 3 | 60% | 0.3% | 3 |
| 4 | BEZAFIBRATE INFARCT PREVENT STUDY COORDINATING CT | 3 | 42% | 0.5% | 5 |
| 5 | ROND POINT NATION | 1 | 38% | 0.3% | 3 |
| 6 | SERV CARDIOL B HEMODYNAM | 1 | 33% | 0.2% | 2 |
| 7 | ARNOLD MARIE WARTZ PHARM ALLIED HLTH | 1 | 50% | 0.1% | 1 |
| 8 | ATEROSCLEROSE | 1 | 50% | 0.1% | 1 |
| 9 | CANADIAN SOC ENDOCRINOL METAB | 1 | 50% | 0.1% | 1 |
| 10 | CLIN PHARMACOKINET TOXICOKINET | 1 | 50% | 0.1% | 1 |
Related classes at same level (level 1) |
| Rank | Relatedness score | Related classes |
|---|---|---|
| 1 | 0.0000135905 | PRAVASTATIN//HMG COA REDUCTASE INHIBITOR//COMPACTIN |
| 2 | 0.0000125574 | LAROPIPRANT//NIACIN//HM74A |
| 3 | 0.0000110376 | PROBUCOL//AGI 1067//SUCCINOBUCOL |
| 4 | 0.0000099601 | GRADIENT GEL ELECTROPHORESIS//SMALL DENSE LDL//FAMILIAL COMBINED HYPERLIPIDEMIA |
| 5 | 0.0000095232 | EZETIMIBE//CHOLESTEROL ABSORPTION INHIBITOR//COLESEVELAM |
| 6 | 0.0000094145 | STATINS//LOW DENSITY LIPOPROTEIN CHOLESTEROL//ATORVASTATIN |
| 7 | 0.0000090286 | STATIN MYOPATHY//STATIN INTOLERANCE//MYALGIA |
| 8 | 0.0000090052 | PPAR DELTA//PPAR BETA DELTA//PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA |
| 9 | 0.0000073881 | NK 104//PITAVASTATIN//CAS 147526 32 7 |
| 10 | 0.0000070312 | PEROXISOME PROLIFERATORS//PEROXISOME PROLIFERATOR//3 THIA FATTY ACIDS |